The mismatch repair gene MSH3 has become a major focus for therapeutic development, as unlike other mismatch repair genes, nullizygosity for MSH3 does not cause malignancies associated with mismatch repair deficiency. The gene discussed is ENSG00000280371; the disease is mismatch repair cancer syndrome 1.